A Phase 3 interventional study of Plozasiran and Placebon in Familial Chylomicronemia Syndrome, sponsored by Visirna Therapeutics HK Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Visirna Therapeutics HK Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blinded, placebo controlled, two periods phase 3 clinical study. The primary objective of the study was to evaluate the efficacy and safety of Plozasiran injection in Chinese adults with familial chylomicronemia syndrome (FCS). A total of 37 participants were enrolled in the study. The duration of the study randomized period was approximately 112 weeks, including a screening period of up to 8 weeks and a treatment period of up to 104 weeks. Participants who completed the randomized period will continue in a 1-year open-label extension period where all participants will receive Plozasiran.
Visirna Therapeutics HK Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diabetes mellitus with any of the following:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plozasiran 25 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months
Drug: Plozasiran
Plozasiran 50 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months
Drug: Plozasiran
Matching placebo administered every 3 months for 12 months
Drug: Placebon
Subcutaneous injection
Also known as: ARO-APOC3, SAR449124, VSA001
Subcutaneous injection
Also known as: Normal saline
Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10
Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 was defined as geometric mean of 2 measurements taken during Month 10, or the other non-missing measurement if any one of the two measurements was missing during Month 10. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum was imputed mainly based on the Pattern Mixture Models (PMM). Descriptive statistics were calculated based on non-imputed data.
Time frame: Baseline to Month 10
Percent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged)
Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 and Month 12 was defined as the geometric mean of the measurements in Month 10 and Month 12 or the non-missing measurement in the other month if measurement in any one of the two months was missing. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum TG was imputed mainly based on the PMM. Descriptive statistics were calculated based on non-imputed data.
Time frame: Baseline to Months 10 and 12 (averaged)
Percent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10
Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.
Time frame: Baseline to Month 10
Percent Change From Baseline in Fasting Serum APOC3 at Month 12
Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.
Time frame: Baseline to Month 12
Percent Change From Baseline in Fasting Serum Non-high Density Lipoprotein Cholesterol (Non-HDL-C) and High Density Lipoprotein Cholesterol (HDL-C) at Month 10
Blood samples for lipid parameters were collected at the specified time points. Baseline was defined as the last non-missing value prior to or on the first dosing date.
Time frame: Baseline to Month 10
Percent Change From Baseline in Fasting Serum TG, Non-HDL-C, and HDL-C at Month 12
Blood samples for lipid parameters were collected at the specified time points. Non-HDL-C and HDL-C baseline was defined as the last non-missing value prior to or on the first dosing date.
Time frame: Baseline to Month 12
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 10
Blood samples for lipid parameters were collected at the specified time points.
Time frame: 10 Month
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 12
Blood samples for lipid parameters were collected at the specified time points.
Time frame: 12 Month
Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12
Blood samples for lipid parameters were collected at the specified time points.
Time frame: From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12
Percent Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12
Blood samples for lipid parameters were collected at the specified time points.
Time frame: From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12
Number of Participants With Positively Adjudicated Events of Acute Pancreatitis
Any AEs and SAEs reported by the investigator during the study that were consistent with acute pancreatitis events were adjudicated by the blinded Data Safety Committee based on the Atlanta Classification for Acute Pancreatitis 2013 for fulfillment of any 2 of the following 3 criteria: 1. Abdominal pain consistent with symptoms of acute pancreatitis (acute episodes of persistent, severe upper abdominal pain often radiating to the back) 2. Serum lipase activity (or amylase activity) ≥3 × upper limit of normal (ULN) 3. Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) or transabdominal ultrasonography
Time frame: From first administration of study treatment (Day 1) through Month 12.
A total of 63 participants were screened from 10-July-2023 to 19-Jan-2024, of which 26 participants were screen failures mainly due to selection criteria not met.
| Milestone | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Started | 12 | 12 | 13 |
| Completed | 10 | 11 | 11 |
| Not completed | 2 | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Poor compliance and unable to receive treatment and attend visits as scheduled | 1 | 0 | 0 |
| Withdrew: Other reason | 0 | 0 | 1 |
| Withdrew: Subjects were transfered to the extension phase after unblinding due to an acute pancreatitis event | 0 | 0 | 1 |
Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 was defined as geometric mean of 2 measurements taken during Month 10, or the other non-missing measurement if any one of the two measurements was missing during Month 10. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum was imputed mainly based on the Pattern Mixture Models (PMM). Descriptive statistics were calculated based on non-imputed data.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10 | -85.7 (-97.3 to -43.9) | -89.5 (-94.7 to -18.1) | 38.8 (-56.2 to 136.7) |
Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 and Month 12 was defined as the geometric mean of the measurements in Month 10 and Month 12 or the non-missing measurement in the other month if measurement in any one of the two months was missing. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum TG was imputed mainly based on the PMM. Descriptive statistics were calculated based on non-imputed data.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged) | -82.1 (-96.8 to -41.5) | -86.6 (-93.3 to -26.1) | 49.5 (-56.4 to 457.7) |
Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10 | -92.55 (-97.57 to -85.70) | -91.83 (-99.78 to -84.19) | 19.91 (-28.35 to 79.48) |
Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Fasting Serum APOC3 at Month 12 | -83.98 (-93.41 to -13.93) | -88.16 (-94.83 to -71.13) | 22.56 (-29.38 to 334.31) |
Blood samples for lipid parameters were collected at the specified time points. Baseline was defined as the last non-missing value prior to or on the first dosing date.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent change in fasting serum Non-HDL-C | -37.76 (-63.8 to 37.5) | -17.83 (-58.0 to 360.4) | 40.34 (-3.1 to 218.2) |
| Percent change in fasting serum HDL-C | 71.62 (0.0 to 166.1) | 86.84 (47.7 to 190.2) | -3.51 (-43.1 to 14.3) |
Blood samples for lipid parameters were collected at the specified time points. Non-HDL-C and HDL-C baseline was defined as the last non-missing value prior to or on the first dosing date.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent change in fasting serum TG | -71.56 (-96.2 to 59.1) | -79.22 (-92.5 to -13.4) | 79.41 (-62.1 to 1213.9) |
| Percent change in fasting serum Non-HDL-C | -7.21 (-48.6 to 63.3) | -29.22 (-61.7 to 315.4) | 40.67 (-2.3 to 96.7) |
| Percent change in fasting serum HDL-C | 51.32 (-23.2 to 130.4) | 65.33 (21.5 to 178.4) | -11.86 (-93.3 to 40.4) |
Blood samples for lipid parameters were collected at the specified time points.
| Percentage of participants | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 10 | 90.0 | 81.8 | 9.1 |
Blood samples for lipid parameters were collected at the specified time points.
| Percentage of participants | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 12 | 60.0 | 72.7 | 18.2 |
Blood samples for lipid parameters were collected at the specified time points.
| mmol/L | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Change from baseline in fasting serum TG at month 1 | -12.716 (-33.29 to -4.40) | -13.610 (-24.48 to -7.87) | 0.568 (-15.04 to 10.30) |
| Change from baseline in fasting serum TG at month 2 | -12.029 (-34.49 to -6.11) | -10.892 (-18.72 to 0.15) | -3.079 (-16.56 to 59.98) |
| Change from baseline in fasting serum TG at month 3 | -9.789 (-35.00 to -2.65) | -12.248 (-27.59 to -0.49) | -4.617 (-14.28 to 12.60) |
| Change from baseline in fasting serum TG at month 4 | -11.849 (-35.81 to -6.55) | -15.933 (-27.27 to -7.69) | 0.372 (-7.28 to 21.88) |
| Change from baseline in fasting serum TG at month 5 | -11.804 (-34.98 to 0.62) | -11.967 (-20.50 to -4.98) | -2.778 (-9.19 to 25.40) |
| Change from baseline in fasting serum TG at month 6 | -11.434 (-34.96 to 8.34) | -12.921 (-29.17 to -7.74) | -1.008 (-9.81 to 54.54) |
| Change from baseline in fasting serum TG at month 7 | -14.784 (-35.59 to -7.50) | -14.279 (-33.73 to -1.95) | -0.809 (-8.87 to 10.15) |
| Change from baseline in fasting serum TG at month 8 | -10.856 (-35.56 to -1.49) | -8.815 (-31.97 to 32.42) | -2.684 (-7.73 to 23.63) |
| Change from baseline in fasting serum TG at month 9 | -9.684 (-34.83 to -4.30) | -11.134 (-26.37 to 8.07) | -2.325 (-7.86 to 24.53) |
| Change from baseline in fasting serum TG at month 10 | -12.124 (-35.57 to -7.09) | -11.667 (-23.97 to -5.57) | 3.794 (-8.40 to 16.34) |
| Change from baseline in fasting serum TG at month 11 | -10.674 (-35.22 to 14.64) | -14.040 (-25.62 to -6.41) | -0.453 (-7.87 to 12.34) |
| Change from baseline in fasting serum TG at month 12 | -10.208 (-35.19 to 12.17) | -13.750 (-35.50 to -1.37) | 10.627 (-12.76 to 102.27) |
Blood samples for lipid parameters were collected at the specified time points.
| Percent change | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Percent change from baseline in fasting serum TG at month 1 | -87.17 (-94.1 to -37.0) | -91.71 (-96.8 to -42.6) | 3.86 (-73.4 to 55.1) |
| Percent change from baseline in fasting serum TG at month 2 | -87.31 (-94.3 to -58.3) | -81.86 (-95.2 to 0.3) | -30.22 (-80.8 to 377.3) |
| Percent change from baseline in fasting serum TG at month 3 | -84.49 (-95.7 to -10.1) | -77.24 (-96.8 to -2.3) | -47.54 (-71.6 to 129.0) |
| Percent change from baseline in fasting serum TG at month 4 | -91.24 (-97.9 to -25.3) | -87.47 (-95.5 to -60.9) | -4.74 (-63.8 to 126.8) |
| Percent change from baseline in fasting serum TG at month 5 | -89.10 (-95.7 to 6.8) | -88.04 (-94.5 to -25.8) | -22.44 (-56.5 to 341.3) |
| Percent change from baseline in fasting serum TG at month 6 | -83.97 (-95.6 to 40.5) | -75.58 (-96.6 to -56.3) | -4.92 (-68.6 to 732.8) |
| Percent change from baseline in fasting serum TG at month 7 | -89.17 (-97.3 to -77.8) | -87.41 (-96.3 to -14.4) | -10.27 (-62.0 to 103.9) |
| Percent change from baseline in fasting serum TG at month 8 | -82.13 (-97.2 to -13.8) | -70.49 (-92.9 to 128.1) | -27.06 (-54.8 to 191.3) |
| Percent change from baseline in fasting serum TG at month 9 | -78.53 (-95.7 to -16.3) | -82.26 (-93.8 to 40.2) | -22.94 (-52.5 to 251.1) |
| Percent change from baseline in fasting serum TG at month 10 | -85.69 (-97.3 to -43.9) | -89.46 (-94.7 to -18.1) | 38.84 (-56.2 to 136.7) |
| Percent change from baseline in fasting serum TG at month 11 | -75.00 (-96.3 to 71.1) | -86.11 (-95.6 to -30.7) | -3.67 (-55.0 to 133.6) |
| Percent change from baseline in fasting serum TG at month 12 | -71.56 (-96.2 to 59.1) | -79.22 (-92.5 to -13.4) | 79.41 (-62.1 to 1213.9) |
Any AEs and SAEs reported by the investigator during the study that were consistent with acute pancreatitis events were adjudicated by the blinded Data Safety Committee based on the Atlanta Classification for Acute Pancreatitis 2013 for fulfillment of any 2 of the following 3 criteria: 1. Abdominal pain consistent with symptoms of acute pancreatitis (acute episodes of persistent, severe upper abdominal pain often radiating to the back) 2. Serum lipase activity (or amylase activity) ≥3 × upper limit of normal (ULN) 3. Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) or transabdominal ultrasonography
| Participants | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Number of Participants With Positively Adjudicated Events of Acute Pancreatitis | 0 | 0 | 1 |
Collected over Adverse events (AE) data was collected from first dose of study treatment (Day 1) up to the Month 12. The data collection is ongoing for the Open-Label Extension period and the AE section will be updated after study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Plozasiran 25 mg | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Plozasiran 50 mg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Placebo | 0/13 (0%) | 4/13 (30.8%) | 12/13 (92.3%) |
| Event | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Foot fractureInjury, poisoning and procedural complications | 1/12 | 0/12 | 0/13 |
| Renal hydroceleRenal and urinary disorders | 1/12 | 0/12 | 0/13 |
| UreterolithiasisRenal and urinary disorders | 1/12 | 0/12 | 0/13 |
| Abdominal distensionGastrointestinal disorders | 0/12 | 0/12 | 1/13 |
| Pancreatitis acuteGastrointestinal disorders | 0/12 | 0/12 | 1/13 |
| Duodenal ulcerGastrointestinal disorders | 0/12 | 0/12 | 1/13 |
| Cholecystitis acuteHepatobiliary disorders | 0/12 | 0/12 | 1/13 |
| Event | Plozasiran 25 mg | Plozasiran 50 mg | Placebo |
|---|---|---|---|
| Hepatic function abnormalHepatobiliary disorders | 2/12 | 5/12 | 4/13 |
| Upper respiratory tract infectionInfections and infestations | 4/12 | 2/12 | 1/13 |
| Alanine aminotransferase increasedInvestigations | 3/12 | 3/12 | 1/13 |
| Aspartate aminotransferase increasedInvestigations | 3/12 | 2/12 | 2/13 |
| Influenza like illnessGeneral disorders | 3/12 | 3/12 | 2/13 |
| Blood creatine phosphokinase increasedInvestigations | 0/12 | 0/12 | 3/13 |
| Lipase increasedInvestigations | 0/12 | 2/12 | 1/13 |
| Abdominal painGastrointestinal disorders | 2/12 | 1/12 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 1/12 | 0/13 |
| ConstipationGastrointestinal disorders | 2/12 | 0/12 | 0/13 |
| Age, Categorical(Participants) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 13 | 37 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 4 | 2 | 3 | 9 |
| Male | 8 | 10 | 10 | 28 |
| Race/Ethnicity, Customized(Participants) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| Race — Asian | 12 | 12 | 13 | 37 |
| Race — Others | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Han | 11 | 12 | 12 | 35 |
| Ethnicity — Others | 1 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| China | 12 | 12 | 13 | 37 |
| Fasting serum TG (mg/dL)(mg/dL) | Plozasiran 25 mg | Plozasiran 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 1786.1 ± 894.04 | 1640.2 ± 856.15 | 1250.2 ± 444.26 | 1550.5 ± 766.64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2023 to primary completion in Nov 2024, 16 months.
Results were first posted in Feb 2026, 1 year 3 months after primary completion. A results delay was requested in Nov 2025.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plozasiran
Familial hyperchylomicronemia syndrome
Visirna Therapeutics HK Limited